KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma. PMID 41617395 · J Immunother Cancer · 2026-Jan-30 The record describes a Phase III randomized trial with a drug intervention, reporting original Kaplan-Meier OS results, meeting all inclusion criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 2 Figure · 6 Panel · risk not_visible
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. PMID 41617393 · J Immunother Cancer · 2026-Jan-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial. PMID 41617358 · RMD Open · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Mobilization Facilitated by Wearable Device Enhanced Patient Monitoring/Electrophysiology Pod-Based Feedback on Postoperative Complications Following Colorectal Cancer Surgery: Randomized Controlled Trial. PMID 41616372 · JMIR Mhealth Uhealth · 2026-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium. PMID 41611967 · Eur J Hum Genet · 2026-Jan-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating the impact of age on prostate cancer overdiagnosis using long-term follow-up from a randomised trial. PMID 41646805 · medRxiv · 2026-Jan-28 The study is a randomized trial in oncology (prostate cancer) with long-term follow-up, but it does not involve a drug-containing intervention (PSA screening is diagnostic) and does not have a time-to-event efficacy endpoint (it measures overdiagnosis incidence, not survival outcomes). Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the impact of financial navigation on financial catastrophe and distress for cancer care: a randomized control trial-COST-FIN. PMID 41606671 · Trials · 2026-Jan-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial. PMID 41605963 · NPJ Breast Cancer · 2026-Jan-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Family-Centered Advance Care Planning in Patients With Breast Cancer: A Randomized Controlled Trial in China. PMID 41604160 · Omega (Westport) · 2026-Jan-28 The record describes a randomized trial in oncology patients, but it is ineligible because it is not a drug intervention trial, does not report time-to-event efficacy endpoints, and the phase is not established as definitive Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. PMID 41604000 · J Neurooncol · 2026-Jan-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. PMID 41593669 · BMC Med · 2026-Jan-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. PMID 41593108 · NPJ Breast Cancer · 2026-Jan-27 The record describes a randomized oncology trial with human patients and time-to-event endpoints (iDFS, OS). However, it is excluded because it lacks a drug-containing intervention; it compares surgical procedures only.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. PMID 41591582 · Cancer Immunol Immunother · 2026-Jan-27 The record is an extended follow-up of a randomized controlled trial with an oncology endpoint (RFS) and a drug/cell-based intervention. However, the phase of the original trial is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. It is described as a 'randomized controlled trial' but the specific trial phase is not provided, preventing definitive inclusion based on the required phase criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study. PMID 41591537 · Cancer Immunol Immunother · 2026-Jan-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. PMID 41589607 · Am J Clin Oncol · 2026-Jan-26 The record is a systematic review and meta-analysis, which is an excluded report type. It does not meet the criterion for an 'original result' of a single Phase III/IIIb or Phase II/III randomized trial. While it discusses Phase III trials in the conclusion, the included studies' phases are not explicitly established as definitive Phase III/IIIb or Phase II/III in the provided abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Follow-up intensity after colorectal cancer surgery in patients aged ≤ 50, 50-70 and > 70 years - an analysis within the COLOFOL randomised clinical trial. PMID 41586910 · Int J Colorectal Dis · 2026-Jan-26 The study is a randomized trial of follow-up intensity after colorectal cancer surgery. It reports 5-year mortality and recurrence risks (risk differences), not time-to-event endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. It lacks a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. PMID 41681846 · Cancers (Basel) · 2026-Jan-25 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Stroma-driven intertumoral and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation. PMID 41587324 · Hepatology · 2026-Jan-24 The record describes a retrospective biomarker and prognostic analysis of intrahepatic cholangiocarcinoma, not the formal results of a randomized clinical trial. It lacks all key trial elements: randomization, a defined phase, a drug-containing intervention arm, and a primary time-to-event efficacy endpoint. The discussion of immune checkpoint inhibitors is contextual, not as an evaluated intervention in this study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. PMID 41575674 · Fam Cancer · 2026-Jan-23 The record describes a pilot study for a non-drug educational intervention, with no randomized trial results, no drug intervention, and no time-to-event endpoint reported.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. PMID 41577609 · Eur Urol Oncol · 2026-Jan-22 The record is an original secondary analysis (prognostic factor study) from the VESPER trial, not the primary efficacy report. The abstract does not explicitly state the trial phase (Phase III/IIIb or Phase II/III), and the deterministic review notes phase evidence is unclear. While it meets criteria for oncology, human, randomized, drug intervention, and time-to-event endpoint, it fails the 'phase3_or_definitive' criterion and is not the primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness and cost-effectiveness of ozone treatment in patients with paraesthesia (numbness, tingling) secondary to chemotherapy-induced peripheral neuropathy: randomized, triple-blind clinical trial (OzoParQT). PMID 41572235 · BMC Cancer · 2026-Jan-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of a behavioral counseling for adoption and maintenance of a physically active lifestyle on long-term mortality in people with type 2 diabetes: post hoc analysis of the Italian Diabetes and Exercise Study_2. PMID 41571659 · Nat Commun · 2026-Jan-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial. PMID 41570298 · JMIR Res Protoc · 2026-Jan-22 The record is a protocol for an ongoing randomized controlled trial. It does not contain formal results from a completed Phase III/IIIb or Phase II/III randomized trial with a primary time-to-event efficacy endpoint. The phase is unclear, and it is explicitly not a result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy of complex decongestive therapy in the treatment of lymphedema associated with endometrial and cervical cancer: evaluation of sensation and balance. PMID 41569453 · Support Care Cancer · 2026-Jan-22 The study is an oncology-related randomized trial in humans, but it lacks a drug-containing intervention, is not Phase III/IIIb or Phase II/III, and does not have a time-to-event efficacy endpoint. It evaluates a physical therapy intervention for lymphedema symptoms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN. PMID 41646304 · Res Sq · 2026-Jan-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. PMID 41595753 · Biomedicines · 2026-Jan-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial. PMID 41565552 · Eur Urol Oncol · 2026-Jan-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Lung Cancer Screening, Smoking Cessation, and Cessation Smartphone App to Health-Related Quality of Life Among Heavy Smokers: Randomized Controlled Trial. PMID 41557895 · J Med Internet Res · 2026-Jan-20 Study is a randomized controlled trial in the context of lung cancer screening, but it evaluates health-related quality of life as an exploratory endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Additionally, the intervention is a smoking cessation smartphone app, not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term survival outcomes of laparoscopic total gastrectomy vs open total gastrectomy in patients with clinical stage I gastric cancer the CLASS02 randomized clinical trial. PMID 41556169 · Int J Surg · 2026-Jan-20 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. PMID 41385757 · J Clin Oncol · 2026-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial. PMID 41553596 · J Neurooncol · 2026-Jan-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial. PMID 41546786 · Cancer Causes Control · 2026-Jan-17 The study is a randomized controlled trial in oncology (prostate cancer) with human subjects and original results, but it is excluded because it lacks a drug-containing intervention (exercise vs. usual care) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary endpoints are biomarkers (insulin, inflammation, PSA), not survival or progression outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung). PMID 41389771 · Eur J Cancer · 2026-Jan-17 The record does not explicitly confirm the trial phase as Phase III, Phase IIIb, or Phase II/III. The abstract describes a 'feasibility' study with 60 patients, and the publication types do not specify phase. The deterministic review signal 'phase3_evidence_unclear' supports this exclusion. While all other eligibility criteria are met, the required phase criterion is not established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. PMID 41365069 · Eur J Cancer · 2026-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. PMID 41545349 · Nat Commun · 2026-Jan-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of nurse navigation and mobile app on brain tumor patients receiving oral anticancer therapy. PMID 41540229 · NPJ Digit Med · 2026-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial. PMID 41533333 · Cancer · 2026-Jan-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial. PMID 41118594 · Blood · 2026-Jan-15 The record is an original result report of a Phase III oncology trial with a drug intervention and primary time-to-event endpoints (EFS, OS). However, the abstract does not explicitly state that the trial was randomized. Without confirmation of randomization, it cannot be classified as a definitive randomized controlled trial eligible for the cohort. The report is an interim analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Open versus laparoscopic ablation of liver malignancies - a protocol for a randomised clinical trial. PMID 41736646 · Dan Med J · 2026-Jan-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
An App-Based Behavioral Support Intervention Promoting Physical Activity (APPROACH) in Patients Diagnosed With Breast, Prostate, or Colorectal Cancer: Protocol for a Randomized Controlled Trial. PMID 41529252 · JMIR Res Protoc · 2026-Jan-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence. PMID 41646795 · medRxiv · 2026-Jan-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized controlled trial. PMID 41526867 · BMC Cancer · 2026-Jan-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis. PMID 41526345 · Nat Commun · 2026-Jan-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Roy adaptation model-based patient education for elderly patients undergoing laparoscopic radical gastrectomy. PMID 41524904 · Support Care Cancer · 2026-Jan-12 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
ERNIE-Evaluating Response to an individualized Neuropsychological IntervEntion for children with brain tumors: study protocol for a randomized controlled trial. PMID 41514361 · Trials · 2026-Jan-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease. PMID 41264726 · J Crohns Colitis · 2026-Jan-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of gut barrier dysfunction during a viral respiratory disease challenge on immune function of feedlot beef calves. PMID 41968102 · J Anim Sci · 2026-Jan-08 仅见动物/临床前证据,不是人体临床试验。
B
仅广召回影子组 excludednon_human pending 0 Figure · 0 Panel · risk -
Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis. PMID 40971670 · Rheumatology (Oxford) · 2026-Jan-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Home-based patient-centered physical activity program for quality of life preservation during neoadjuvant chemotherapy in breast cancer: the AURORA randomized controlled trial protocol. PMID 41501916 · Trials · 2026-Jan-07 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial. PMID 41491437 · BMC Cancer · 2026-Jan-06 The study is a randomized controlled trial with primary time-to-event efficacy endpoints (PFS and OS) in human oncology. However, it is excluded because the intervention is a non-drug dietary regimen (probiotics, prebiotics, dietary advice) and does not meet the requirement for a drug-containing intervention. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -